Loading clinical trials...

COMPLETEDPHASE2

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma

NCT00054886•Pfizer

Summary

The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer.
•The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given.
•Any side effects from prior therapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function

Exclusion Criteria

•Prior treatment with any systemic therapy other than 1 prior cytokine-based treatment regimen;
•Prior surgical resection of or irradiation to the only site of measurable disease;
•Ongoing severe hematuria;
•Other active second malignancy;
•Cardiovascular diseases or conditions within the last 12 months;
•Known brain metastases;
•Known HIV-positive or AIDS-related illness;
•Pregnant or breast-feeding women;
•Current participation in other clinical trials;
•Other severe acute or chronic medical conditions.

Locations (15)

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Mission Hills, California, United States

Pfizer Investigational Site

Monterey Park, California, United States

Pfizer Investigational Site

Northridge, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

San Francisco, California, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Pfizer Investigational Site

Henderson, Nevada, United States

Key Dates

Start Date

January 1, 2003

Completion Date

August 1, 2004

Last Updated

May 7, 2007

Enrollment

Estimated participants

Conditions

Kidney Neoplasms

Interventions

SU-011,248

DRUG

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

NCT07225114

Breast CancerKidney Neoplasms+1 more

View study

RECRUITINGPHASE2

CD70-targeted immunoPET Imaging of Kidney Cancer

NCT06680089

Urologic NeoplasmsUrogenital Neoplasms+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Inclusion Criteria

Exclusion Criteria

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

CD70-targeted immunoPET Imaging of Kidney Cancer

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool

MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy